Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

351

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

351 results for “empagliflozin”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov28/100

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

ClinicalTrials.gov study NCT01111331. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

ClinicalTrials.gov study NCT04098575. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

ClinicalTrials.gov study NCT04937816. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

ClinicalTrials.gov study NCT03629054. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

ClinicalTrials.gov study NCT06021145. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Empagliflozin Versus Linagliptin in Renal Ransplant Recipients With Diabetes Mellitus

ClinicalTrials.gov study NCT06098625. IPD Sharing: NO. Countries: 0. Publications: 7.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

ClinicalTrials.gov study NCT04233801. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability

ClinicalTrials.gov study NCT01211197. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
geo24/100

RNA-expression analysis on smooth muscle cells of diabetic donors after empagliflozin treatment

GEO Series GSE189538. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2021View details →
geo24/100

Empagliflozin Ameliorates Aldehyde Dehydrogenase 2 Deficiency-induced Endothelial Dysfunction

GEO Series GSE184419. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenMar 2023View details →
geo24/100

Empagliflozin in acute myocardial infarction reduces no-reflow and preserves cardiac function by preventing endothelial damage

GEO Series GSE255933. Mus musculus. 38 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenSep 2024View details →
geo24/100

Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells

GEO Series GSE243752. Rattus norvegicus. 6 samples. Type: Expression profiling by high throughput sequencing.

openGEO-OpenNov 2023View details →
zenodo24/100

Figure 2 from: Obaid KA, Fawzi HA (2024) Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study. Pharmacia 71: 1-9. https://doi.org/10.3897/pharmacia.71.e116184

Figure 2 Assessment of inflammatory and oxidative stress markers.

opencc-by-4.0Jan 2024View details →
zenodo24/100

Figure 3 from: Obaid KA, Fawzi HA (2024) Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study. Pharmacia 71: 1-9. https://doi.org/10.3897/pharmacia.71.e116184

Figure 3 Assessment of COL-1 and -3 levels.

opencc-by-4.0Jan 2024View details →
zenodo24/100

Figure 1 from: Obaid KA, Fawzi HA (2024) Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study. Pharmacia 71: 1-9. https://doi.org/10.3897/pharmacia.71.e116184

Figure 1 Flow chart of the study.

opencc-by-4.0Jan 2024View details →
ClinicalTrials.gov24/100

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

ClinicalTrials.gov study NCT06683053. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

ClinicalTrials.gov study NCT04918407. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

ClinicalTrials.gov study NCT02985242. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov24/100

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

ClinicalTrials.gov study NCT07038356. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov24/100

Empagliflozin in Pulmonary Arterial Hypertension

ClinicalTrials.gov study NCT05493371. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record